CDER, CBER Heads Avoid Weighing In On IRA Innovation Impacts

While emphasizing FDA’s support for innovative drug development, the directors of FDA’s drugs and biologics centers declined to comment on how the Inflation Reduction Act’s (IRA) Medicare drug price negotiation program could impact investment in drug research and development, when asked by House lawmakers Wednesday (May 22) for their take on recent remarks by a high-level biologics official that the law is deterring some investment. The center directors were asked about the issue by Rep. Buddy Carter (R-GA), who described...